Biotech in general is still pretty hot, and orphan drugs development is
hotter still. Even allowing for that background of bullishness, I think
there may be worthwhile value still remaining in the shares of Prothena (PRTA).
It must be noted, though, that Prothena is extremely early-stage and in
more normal markets I would expect analysts and investors to assign
much lower odds to the company's pipeline. Even so, the science here
appears pretty solid and Prothena has the added benefit of backing from
the world's largest developer of antibodies.
Click this link to continue:
Prothena's Early-Stage Assets Hold Exciting Potential
No comments:
Post a Comment